Annuaire IPHC

DSA | Synthèse Pour l’Analyse (SynPA) » Research Interests » 64Cu radiolabeled nanomaterials for diagnostic and radiotherapy

64Cu radiolabeled nanomaterials for diagnostic and radiotherapy

Dernière mise à jour : mercredi 9 janvier 2013, par Aline NONAT

Every year 3.2 million Europeans are diagnosed with cancer. Although great advances continue to be made in research and treatments, cancer remains a key health concern. In this context, there is a need for new diagnostic and therapeutic strategies for early detection and treatment of the disease.

Non-invasive medical imaging techniques such as Magnetic Resonance Imaging (MRI), nuclear imaging and optical imaging are powerful tools for medical diagnostic. However, none of these techniques is able to establish a comprehensive and accurate diagnostic at an early stage of a disease.

We are interested in combining if the strengths of two complementary imaging methods (PET and optical imaging) in a single multimodal agent, in order to collect sufficient information with high sensitivity and spatial resolution.

Our researches in this area, aim to develop semiconductor nanocristals with unique optical properties and to functionnalise their surface with bispidone ligands for the complexation of 64Cu.

Water soluble quantum dots with tuneable optical properties have been synthesized and currents efforts are directed towards the functionnalisation of these nanocristals.

Bispidone are highly rigid and preorganized ligands which should provide very stable Cu(II) complexes. Several ligands have been synthesized. [1] The physico-chemical evaluation of their transition metal complexes is in progress.

[1T. Legdali, A. Roux, A. M. Nonat, C. Platas-Iglesias, L. J. Charbonnière, J. Org. Chem., 2012, 77, 11167-11176